HRTX - Heron Narxning prognoz qilingan daromadga nisbati

Heron Therapeutics, Inc. (HRTX) - korporativ logo

Heron Therapeutics (HRTX) AQSh shifoxonalari bo'yicha o'z mavjudligini kengaytirishi mumkinmi? Tashkilotning prognoz qilingan P/S ko'rsatkichi bunga javob beradi, uning joriy qiymati 0.40 ni tashkil etadi. Grafik dinamikasi Zynrelefa sotuvlarining o'sish potentsialini va daromadli bo'lish yo'lini baholashga yordam beradi. Ximioterapiya natijasida kelib chiqqan ko'ngil aynishi va og'riqlarni davolash usullarining muvaffaqiyatli joriy etilishi tibbiyot sektorida bozor ulushi uchun kurashning samaradorligini tasdiqlaydi.

Heron Therapeutics Inc - HRTX Prognoz narxning daromadga nisbati (davr: 04.07.2022 - 17.11.2026)

Heron Therapeutics Inc (HRTX) boʻyicha keng qamrovli koʻrsatkichlar kesimi va tahlil

- bozor narxi va tahlilchilarning maqsadli narxlari:
- bozor kapitallashuvi statistikasi:
Kompaniyaning umumiy tahlili:Heron Therapeutics, Inc. HRTX
Heron tomonidan chiqariladigan mahsulotlar

Heron Therapeutics (HRTX) uchun 0.40 miqdoridagi forward daromad koeffitsienti biznesning bozor qiymatini kutilayotgan savdo hajmi bilan nisbatda aks ettiradi. Ushbu ko'rsatkich joriy bozor kapitalizatsiyasini prognoz qilingan daromad oqimlari bilan bog'laydi, bu esa bozorni agressiv kengaytirish va ichki xarajatlarni optimallashtirish davrida kompaniyaning baholanishi adolatli ekanligini tahlil qilish imkonini beradi.

Muhim raqobatchilar

Narxning prognoz qilingan daromadga nisbati Incyte Corp. INCY|HUTCHMED Ltd (HCM) - Bozor kapitallashuvining kelajakdagi daromadga nisbati|NUVB - Narxning prognoz qilingan daromadga nisbati|Bozor kapitallashuvining kelajakdagi daromadga nisbati Day One|MNPR: Forvard P/S multiplikatori|Prognoz narxning daromadga nisbati Inhibrx Biosciences Inc INBX|Forvard narx/daromad multiplikatori IMAB|Bozor kapitallashuvining kelajakdagi daromadga nisbati Fennec Pharmaceuticals FENC|Forvard narx/daromad multiplikatori NVCT (Nuvectis Pharma, Inc.)|CHRS (Coherus BioSciences) - Sotuvga nisbatan forvard narx|Corbus Pharmaceuticals - Forvard narx/daromad multiplikatori|Narxning kutilayotgan daromadga nisbati CRDF (Cardiff Oncology Corp)|BeyondSpring Pharma - Forvard P/S multiplikatori|Sotuvga nisbatan forvard narx BCAB (bioatla.com)|LIXT: Forvard P/S multiplikatori|Bozor kapitallashuvining kelajakdagi daromadga nisbati Citius Pharma (CTXR)|Narxning prognoz qilingan daromadga nisbati Cellectar Biosciences, Inc.|BLRX: Sotuvga nisbatan forvard narx|Forvard P/S multiplikatori CANF|Forvard P/S multiplikatori Aprea Therapeutics Inc. (APRE)|Narxning prognoz qilingan daromadga nisbati Kazia Therapeutics Ltd KZIA|SLXN (silexion.com) - Kelajakdagi narxning daromadga nisbati|NCNA: Forvard narx/daromad multiplikatori|Bozor kapitallashuvining kelajakdagi daromadga nisbati Chimerix|CYCC: Forvard P/S multiplikatori|Prognoz narxning daromadga nisbati G1 Therapeutics Inc. GTHX|Narxning prognoz qilingan daromadga nisbati Kronos Bio, Inc.|kintara.com (KTRA) - Kapitalizatsiyaning kutilayotgan sotuvga nisbati|Forvard P/S multiplikatori ONCT|PRTG (Portage) - Sotuvga nisbatan forvard narx